ClinicalTrials.gg
CompletedNCT03405935Updated Dec 1, 2020Results posted

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

A Phase 3 interventional study of B/F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 25 sites in 5 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2020-12-01.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Study summary

The primary objective of this study is to characterize the virologic efficacy of switching virologically suppressed participants on an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) regimen or a tenofovir disoproxil fumarate (TDF) containing regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Currently receiving an antiretroviral regimen of E/C/F/TAF FDC (or emtricitabine [FTC]/TDF + 3rd agent if currently or previously participated in Study GS-US-292-1826 [NCT02616783]) for ≥ 3 months
  • Documented plasma -1 ribonucleic acid (RNA) \< 50 copies/mL during treatment with E/C/F/TAF (or FTC/TDF + 3rd agent if currently or previously participated in Study GS-US-292-1826 [NCT02616783]) for the last 2 visits preceding the screening visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL)
  • Adequate renal function, an estimated (eGFR) ≥ 30 mL/min according to the formula for creatinine clearance

Key Exclusion Criteria:

  • An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening
  • Decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding)
  • Current alcohol or substance use judged by the investigator to potentially interfere with participant study compliance

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    B/F/TAF

    B/F/TAF FDC for at least 96 weeks.

    Drug: B/F/TAF

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the Food and Drug Administration (FDA)-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants Experiencing Adverse Events (AEs) Through Week 24

    An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.

    Time frame: First dose date up to Week 24

  2. Percentage of Participants Experiencing AEs Through Week 48

    An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.

    Time frame: First dose date Up to Week 48

  3. Percentage of Participants Experiencing AEs Through Week 72

    An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.

    Time frame: First dose date Up to Week 72

  4. Percentage of Participants Experiencing AEs Through Week 96

    An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.

    Time frame: First dose date Up to Week 96

  5. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  6. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72 as Defined by the FDA-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 72 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 72

  7. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the FDA-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  8. Change From Baseline in CD4 Cell Count at Week 24

    Time frame: Baseline, Week 24

  9. Change From Baseline in CD4 Cell Count at Week 48

    Time frame: Baseline, Week 48

  10. Change From Baseline in CD4 Cell Count at Week 72

    Time frame: Baseline, Week 72

  11. Change From Baseline in CD4 Cell Count at Week 96

    Time frame: Baseline, Week 96

  12. Change From Baseline in CD4 Percentage at Week 24

    Time frame: Baseline, Week 24

  13. Change From Baseline in CD4 Percentage at Week 48

    Time frame: Baseline, Week 48

  14. Change From Baseline in CD4 Percentage at Week 72

    Time frame: Baseline, Week 72

  15. Change From Baseline in CD4 Percentage at Week 96

    Time frame: Baseline, Week 96

  16. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Analyzed by Missing = Failure Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.

    Time frame: Week 24

  17. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Analyzed by Missing = Failure Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.

    Time frame: Week 48

  18. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72, as Analyzed by Missing = Failure Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 72 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.

    Time frame: Week 72

  19. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96, as Analyzed by Missing = Failure Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.

    Time frame: Week 96

  20. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Analyzed by Missing = Excluded Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).

    Time frame: Week 24

  21. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Analyzed by Missing = Excluded Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).

    Time frame: Week 48

  22. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72, as Analyzed by Missing = Excluded Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 72 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).

    Time frame: Week 72

  23. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96, as Analyzed by Missing = Excluded Approach

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).

    Time frame: Week 96

07

Results

Posted Dec 5, 2019

Participant flow

Participants were enrolled at study sites in Europe. The first participant was screened on 01 March 2018. The last study visit occurred on 29 May 2020.

Participant flow — Overall Study
MilestoneB/F/TAF
Started86
Completed78
Not completed8
Withdrew: Adverse event3
Withdrew: Death2
Withdrew: Withdrawal by subject1
Withdrew: Lost to follow-up2

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the Food and Drug Administration (FDA)-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the Food and Drug Administration (FDA)-Defined Snapshot Algorithm
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the Food and Drug Administration (FDA)-Defined Snapshot Algorithm97.7
SecondaryPercentage of Participants Experiencing Adverse Events (AEs) Through Week 24

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.

Time frame:
First dose date up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Adverse Events (AEs) Through Week 24
percentage of participantsB/F/TAF
Percentage of Participants Experiencing Adverse Events (AEs) Through Week 2462.8
SecondaryPercentage of Participants Experiencing AEs Through Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.

Time frame:
First dose date Up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing AEs Through Week 48
percentage of participantsB/F/TAF
Percentage of Participants Experiencing AEs Through Week 4881.4
SecondaryPercentage of Participants Experiencing AEs Through Week 72

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.

Time frame:
First dose date Up to Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing AEs Through Week 72
percentage of participantsB/F/TAF
Percentage of Participants Experiencing AEs Through Week 7294.2
SecondaryPercentage of Participants Experiencing AEs Through Week 96

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also included pre- or post-treatment complications that occurred as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increased in severity or changed in nature during or as a consequence of participation in the clinical study were also considered AEs.

Time frame:
First dose date Up to Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing AEs Through Week 96
percentage of participantsB/F/TAF
Percentage of Participants Experiencing AEs Through Week 9695.3
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA-Defined Snapshot Algorithm90.7
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72 as Defined by the FDA-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 72 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72 as Defined by the FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72 as Defined by the FDA-Defined Snapshot Algorithm94.2
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the FDA-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined timepoint within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the FDA-Defined Snapshot Algorithm74.4
SecondaryChange From Baseline in CD4 Cell Count at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · cells/µL
Change From Baseline in CD4 Cell Count at Week 24
cells/µLB/F/TAF
Change From Baseline in CD4 Cell Count at Week 2420 ± 141.8
SecondaryChange From Baseline in CD4 Cell Count at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4 Cell Count at Week 48
cells/µLB/F/TAF
Change From Baseline in CD4 Cell Count at Week 488 ± 174.8
SecondaryChange From Baseline in CD4 Cell Count at Week 72
Time frame:
Baseline, Week 72
Reported as:
Mean · cells/µL
Change From Baseline in CD4 Cell Count at Week 72
cells/µLB/F/TAF
Change From Baseline in CD4 Cell Count at Week 7236 ± 145.7
SecondaryChange From Baseline in CD4 Cell Count at Week 96
Time frame:
Baseline, Week 96
Reported as:
Mean · cells/µL
Change From Baseline in CD4 Cell Count at Week 96
cells/µLB/F/TAF
Change From Baseline in CD4 Cell Count at Week 9622 ± 150.9
SecondaryChange From Baseline in CD4 Percentage at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · percentage of lymphocytes
Change From Baseline in CD4 Percentage at Week 24
percentage of lymphocytesB/F/TAF
Change From Baseline in CD4 Percentage at Week 240.1 ± 3.52
SecondaryChange From Baseline in CD4 Percentage at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · percentage of lymphocytes
Change From Baseline in CD4 Percentage at Week 48
percentage of lymphocytesB/F/TAF
Change From Baseline in CD4 Percentage at Week 480.1 ± 3.89
SecondaryChange From Baseline in CD4 Percentage at Week 72
Time frame:
Baseline, Week 72
Reported as:
Mean · percentage of lymphocytes
Change From Baseline in CD4 Percentage at Week 72
percentage of lymphocytesB/F/TAF
Change From Baseline in CD4 Percentage at Week 72-0.1 ± 4.29
SecondaryChange From Baseline in CD4 Percentage at Week 96
Time frame:
Baseline, Week 96
Reported as:
Mean · percentage of lymphocytes
Change From Baseline in CD4 Percentage at Week 96
percentage of lymphocytesB/F/TAF
Change From Baseline in CD4 Percentage at Week 96-0.1 ± 4.34
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Analyzed by Missing = Failure Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Analyzed by Missing = Failure Approach
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Analyzed by Missing = Failure Approach97.7
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Analyzed by Missing = Failure Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Analyzed by Missing = Failure Approach
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Analyzed by Missing = Failure Approach90.7
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72, as Analyzed by Missing = Failure Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 72 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72, as Analyzed by Missing = Failure Approach
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72, as Analyzed by Missing = Failure Approach94.2
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96, as Analyzed by Missing = Failure Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using missing = failure approach. In this approach, all missing data were treated as HIV-1 RNA ≥ 50 copies/mL.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96, as Analyzed by Missing = Failure Approach
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96, as Analyzed by Missing = Failure Approach79.1
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Analyzed by Missing = Excluded Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Analyzed by Missing = Excluded Approach
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Analyzed by Missing = Excluded Approach100.0
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Analyzed by Missing = Excluded Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Analyzed by Missing = Excluded Approach
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Analyzed by Missing = Excluded Approach100.0
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72, as Analyzed by Missing = Excluded Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 72 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72, as Analyzed by Missing = Excluded Approach
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 72, as Analyzed by Missing = Excluded Approach100.0
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96, as Analyzed by Missing = Excluded Approach

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using missing = excluded approach. In this approach, all missing data were excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation).

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96, as Analyzed by Missing = Excluded Approach
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96, as Analyzed by Missing = Excluded Approach100.0

Adverse events

Collected over Adverse Events: First dose of study drug up to last dose plus 30 days (up to Week 102.9); All-Cause Mortality: First dose date up to Week 102.9. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B/F/TAF2/86 (2.3%)9/86 (10.5%)34/86 (39.5%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventB/F/TAF
Atrial fibrillationCardiac disorders1/86
Cardio-respiratory arrestCardiac disorders1/86
Ischaemic cardiomyopathyCardiac disorders1/86
Anal abscessInfections and infestations1/86
Covid-19 pneumoniaInfections and infestations1/86
EndocarditisInfections and infestations1/86
Intentional overdoseInjury, poisoning and procedural complications1/86
Cerebral haemorrhageNervous system disorders1/86
Cerebrovascular accidentNervous system disorders1/86
Ischaemic strokeNervous system disorders1/86
Most frequent other events
Most frequent other events
EventB/F/TAF
BronchitisInfections and infestations10/86
ArthralgiaMusculoskeletal and connective tissue disorders8/86
HypertensionVascular disorders8/86
NasopharyngitisInfections and infestations7/86
DiarrhoeaGastrointestinal disorders6/86
Urinary tract infectionInfections and infestations5/86
SciaticaNervous system disorders5/86

Baseline characteristics

The Safety Analysis Set included all participants who were enrolled and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)B/F/TAF
Mean70 ± 3.8
Sex: Female, Male
Sex: Female, Male(Participants)B/F/TAF
Female11
Male75
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAF
Race — American Indian or Alaska Native0
Race — Asian0
Race — Black1
Race — Native Hawaiian or Pacific Islander0
Race — White82
Race — Other0
Race — Not Permitted3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAF
Ethnicity — Hispanic or Latino12
Ethnicity — Not Hispanic or Latino71
Ethnicity — Not Permitted3
Region of Enrollment
Region of Enrollment(participants)B/F/TAF
Belgium8
France28
Italy22
Spain27
United Kingdom1
Human Immunodeficiency Virus-1 Ribonucleic acid (HIV-1 RNA) Category
Human Immunodeficiency Virus-1 Ribonucleic acid (HIV-1 RNA) Category(Participants)B/F/TAF
< 50 copies/mL84
≥ 50 copies/mL2
Cluster of Differentiation 4 (CD4) Cell Count
Cluster of Differentiation 4 (CD4) Cell Count(cells/µL)B/F/TAF
Mean694 ± 273.6
CD4 Cell Count Category
CD4 Cell Count Category(Participants)B/F/TAF
< 50 cells/µL0
≥ 50 to < 200 cells/µL2
≥ 200 to < 350 cells/µL7
≥ 350 to < 500 cells/µL9
≥ 500 cells/µL68

1 further baseline measures are reported on the registry.

08

Study locations

25 sites
  • CHU Saint-Pierre
    Brussels, 1000, Belgium
  • UZ Gent
    Ghent, 9000, Belgium
  • Hopital Saint-Andre
    Bordeaux, 33075, France
  • Hopital Europeen Marseille
    Marseille, 13006, France
  • C.H.U. de Nantes - Hotel Dieu
    Nantes, 44093, France
  • CHU de Nice
    Nice, 6203, France
  • Hopital Saint Louis
    PARIS cedex 10, 75475, France
  • Hopital Necker - Enfants Malades
    Paris, 75015, France
  • Hopital Saint Antoine
    Paris, 75571, France
  • Interne et Maladies infectieuses
    Pessac, 33064, France
  • CH de Tourcoing
    Tourcoing, 59208, France
  • ASST Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • ASST - Fatebenefratelli Sacco
    Milano, 20157, Italy
  • P.O. Spirito Santo - U.O. Malattie Infettive e Tropicali
    Pescara, 65124, Italy
  • IRCCS Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
    Roma, 00149, Italy
  • Hospital Universitari Germans Trias i Pujol
    Badalona, 8916, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08026, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Costa Del Sol
    Marbella, 29603, Spain
  • Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Newcastle Upon Tyne, NE1 4LP, United Kingdom
09

References and documents

Publications

  • Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, Berenguer J, D'Antoni ML, Blair C, Chuck SK, Piontkowsky D, Martin H, Haubrich R, McNicholl IR, Gallant J. Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged >/= 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial. Infect Dis Ther. 2021 Jun;10(2):775-788. doi: 10.1007/s40121-021-00419-5. Epub 2021 Mar 9. PubMed 33686573 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Nov 2018, 8 months.

Results were first posted in Dec 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2018
First posted
Jan 23, 2018
StartActual
Mar 1, 2018
Primary completionActual
Nov 20, 2018
CompletionActual
May 29, 2020
Results first posted
Dec 5, 2019
Last update
Dec 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03405935
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Mar 1, 2018
Primary completion
Nov 20, 2018
Completion
May 29, 2020
Results posted
Dec 5, 2019
Last update
Dec 1, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion